DDX5 SCREENING METHOD OF COMPOSITION FOR TREATING PROSTATE CANCER COMPRISING DDX5 PROTEIN

摘要

The present invention relates to a diagnostic biomarker composition for predicting the incidence of hormone refractory disease in prostate cancer and a composition for delaying or preventing the occurrence of hormone refractory disease in high-grade prostate cancer or inhibiting hormone refusal in hormone-refractory prostate cancer. The present invention is a composition for treating prostate cancer comprising shRNA or siRNA corresponding to the ccm1 gene to inhibit expression of CCM1 protein. The present invention also provides a composition for treating prostate cancer, which comprises DDX5 protein as an active ingredient. According to the present invention, a composition that can be used as a diagnostic biomarker capable of predicting the occurrence of hormone refractory can be provided.